Drug interactions with newer antidepressants: Role of human cytochromes P450

Journal of Clinical Psychiatry

Volumn 59, Issue SUPPL. 15, 1998, Pages 19-27

  Greenblatt, David J ^a   Von Moltke, Lisa L ^a   Harmatz, Jerold S ^a   Shader, Richard I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; BUFURALOL; CAFFEINE; CARBAMAZEPINE; CHLORZOXAZONE; CITALOPRAM; CLOZAPINE; CYTOCHROME P450; DEBRISOQUINE; DESIPRAMINE; DEXTROMETHORPHAN; DIAZEPAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; KETOCONAZOLE; MIDAZOLAM; MIRTAZAPINE; NEFAZODONE; NIFEDIPINE; OMEPRAZOLE; PAROXETINE; PHENACETIN; PHENYTOIN; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPARTEINE; TERFENADINE; TESTOSTERONE; TOLBUTAMIDE; TRIAZOLAM; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE;

BIOTRANSFORMATION; DEMETHYLATION; DEPRESSION; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; LIVER MICROSOME; PRIORITY JOURNAL; REVIEW;

ANTIDEPRESSIVE AGENTS; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; SEROTONIN UPTAKE INHIBITORS;

EID: 0031694830     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (125)

1. Song F, Freemantle N, Sheldon TA, et al. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 1993;306: 683-687
2. Anderson IM, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol (Oxf) 1994;8:238-249
3. Kasper S, Höflich G, Scholl HP, et al. Safety and antidepressant efficacy of selective serotonin re-uptake inhibitors. Hum Psychopharmacol 1994;9: 1-12
4. Rudorfer MV, Potter WZ. Antidepressants: a comparative review of the clinical pharmacology and therapeutic use of the 'newer' versus the 'older' drugs. Drugs 1989;37:713-738
5. Gram L. Fluoxetine. N Engl J Med 1994;:331:1354-1361
6. Murdoch D, McTavish D. Sertraline: a review of pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder. Drugs 1992;44:604-624
7. Dechant KL, Clissold SP. Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:225-253
8. Nemeroff CB. The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor. Pharmacotherapy 1994;14:127-138
9. Ware MR. Fluvoxamine: a review of the controlled trials in depression. J Clin Psychiatry 1997;58(suppl 5):15-23
10. Palmer KJ, Benfield P. Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs 1994;1:57-87
11. Grimsley SR, Jann MW. Paroxetine, sertraline, and fluvoxamine: new selective serotonin reuptake inhibitors. Clin Pharm 1992;11:930-957
12. Ellingrod VL, Perry PJ. Nefazodone: a new antidepressant. Am J Health Syst Pharm 1995;52:799-812
13. Holliday S, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs 1995;49:280-294
14. Scott MA, Shelton PS, Gattis W. Therapeutic options for treating major depression, and the role of venlafaxine. Pharmacotherapy 1996;16:352-365
15. Milne RJ, Goa KL. Citalopram: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991;41:450-477
16. Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997;17: 10-21
17. Harvey AT, Preskom SH. Cytochrome P450 enzymes: interpretation of their interactions with selective serotonin reuptake inhibitors. J Clin Psychopharmacol 1996;16:273-285, 345-355
18. Ketter TA, Flockhart DA, Post RM, et al. The emerging role of cytochrome P450 3A in psychopharmacology. J Clin Psychopharmacol 1995;15: 387-398
19. van Harten J. Clinical pharmacokinetics of selective serotonin reuptake inhibitors. Clin Pharmacokinet 1993;24:203-220
20. Altamura AC, Moro AR, Percudani M. Clinical pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994;26:201-214
21. Brøsen K. The pharmacogenetics of the selective serotonin reuptake inhibitors. Clin Invest Med 1993;71:1002-1009
22. Baumann P. Pharmacokinetic-pharmacodynamic relationship of the selective serotonin reuptake inhibitors. Clin Pharmacokinet 1996;31:444-469
23. Greenblatt DJ, von Moltke LL, Schmider J, et al. Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies. J Clin Pharmacol 1996;36:792-798
24. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997;32(suppl 1):1-21
25. Rendic S, DiCarlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 1997;29:413-580
26. Gonzalez FJ. Human cytochromes P450: problems and prospects. Trends Pharmacol Sci 1992;13:346-352
27. Guengerich FP. Human cytochrome P-450 enzymes. Life Sci 1992;50: 1471-1478
28. Wrighton SA, Stevens JC. The human hepatic cytochromes P450 involved in drug metabolism. Crit Rev Toxicol 1992;22:1-21
29. Parkinson A. An overview of current cytochrome P450 technology for assessing the safety and efficacy of new materials. Toxicol Pathol 1996; 24:45-57
30. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Cytochromes in psychopharmacology. J Clin Psychopharmacol 1994;14:1-4
31. Ioannides C, ed. Cytochromes P450: Metabolic and Toxicological Aspects. New York, NY: CRC Press; 1996
32. von Moltke LL, Greenblatt DJ, Schmider J, et al. In vitro approaches to predicting drug interactions in vivo. Biochem Pharmacol 1998;55:113-122
33. Bertz RJ, Granneman GR. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 1997;32:210-258
34. Boobis AR. Prediction of inhibitory drug-drug interactions by studies in vitro. In: Pacifici GM, Fracchia GN, eds. Advances in Drug Metabolism in Man. Luxembourg: The European Commission; 1995:513-539
35. Leemann TD, Dayer P. Quantitative prediction of in vivo drug metabolism and interactions from in vitro data. In: Pacifici GM, Fracchia GN, eds. Advances in Drug Metabolism in Man. Luxembourg: The European Commission; 1995:783-830
36. Greenblatt DJ, von Moltke LL. Can in vitro models predict drug interactions in vivo? a review of methods, problems, and successes. In: Hori W, ed. Drug-Drug Interactions: Analyzing In Vitro-In Vivo Correlations. Southboro, Mass: International Business Communications; 1997: 2.2.1-2.2.25
37. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997;32(suppl 1):22-30
38. Sindrup SH, Brøsen K, Hansen MG, et al. Pharmacokinetics of citalopram in relation to the sparteine and the mephenytoin oxidation polymorphisms. Ther Drug Monit 1993;15:11-17
39. Hyttel J, Bøgesø KP, Perregaard J, et al. The pharmacological effect of citalopram resides in the (S) - (+)-enantiomer. J Neural Transm Gen Sect 1992;88:157-160
40. Fuller RW, Snoddy HD, Krushinski JH, et al. Comparison of norfluoxetine enantiomers as serotonin uptake inhibitors in vivo. Neuropharmacology 1992;31:997-1000
41. Sprouse J, Clarke T, Reynolds L, et al. Comparison of the effects of sertraline and its metabolite desmethylsertraline on blockade of central 5-HT reuptake in vivo. Neuropsychopharmacology 1996;14:225-231
42. Kaye CM, Haddock RE, Langley PF, et al. A review of the metabolism and Pharmacokinetics of paroxetine in man. Acta Psychiatr Scand 1989;80 (suppl 350):60-75
43. DeVane CL, Gill HS. Clinical pharmacokinetics of fluvoxamine: applications to dosage regimen design. J Clin Psychiatry 1997;58(suppl 5):7-14
44. Greene DS, Barbhaiya RH. Clinical pharmacokinetics of nefazodone. Clin Pharmacokinet 1997;33:260-275
45. Mayol RF, Cole CA, Luke GM, et al. Characterization of the metabolites of the antidepressant drag nefazodone in human urine and plasma. Drug Metab Dispos 1994;22:304-311
46. Marathe PH, Lee JS, Greene DS, et al. Comparison of the steady-state pharmacokinetics of nefazodone after administration of 200 mg twice daily or 400 mg once daily in the morning or evening. Br J Clin Pharmacol 1996; 41:21-27
47. Howell SR, Husbands GEM, Scatina JA, et al. Metabolic disposition of 14C-venlafaxine in mouse, rat, dog, rhesus monkey and man. Xenobiotica 1993;23:349-359
48. Klamerus KJ, Parker VD, Rudolph RL, et al. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy 1996;16:915-923
49. Troy SM, Parker VD, Fruncillo RJ, et al. The pharmacokinetics of venlafaxine when given in a twice-daily regimen. J Clin Pharmacol 1995;35: 404-49
50. Dahl M-L, Voortman G, Alm C, et al. In vitro and in vivo studies on the disposition of mirtazapine in humans. Clin Drug Invest 1997;1:37-46
51. Kroemer HK, Eichelbaum M. Molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 1995;56: 2285-2298
52. Wilkinson GR, Guengerich FP, Branch RA. Genetic polymorphisms of S-mephenytoin hydroxylation. Pharmacol Ther 1989;43:53-76
53. Gonzalez FJ, Meyer UA. Molecular genetics of the debrisoquin-sparteine polymorphism. Clin Pharmacol Ther 1991;50:233-238
54. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation: current state of knowledge and cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209
55. Bertilsson L, Dahl M-L. Polymorphic drug oxidation: relevance to the treatment of psychiatric disorders. CNS Drugs 1996;3:200-223
56. Linder MW, Prough RA, Valdes R. Pharmacogenetics: a laboratory tool for optimizing therapeutic efficiency. Clin Chem 1997;43:254-266
57. Puga A, Nebert DW, McKinnon RA, et al. Genetic polymorphisms in human drug-metabolizing enzymes: potential uses of reverse genetics to identify genes of toxicological relevance. Crit Rev Toxicol 1997;27:199-222
58. West WL, Knight EM, Pradhan S, et al. Interpatient variability: genetic predisposition and other genetic factors. J Clin Pharmacol 1997;37:635-648
59. Goldstein JA, de Morals SM. Biochemistry and molecular biology of the human CYP2C subfamily. Pharmacogenetics 1994;4:285-299
60. Gelboin HV. Cytochrome P450 and monoclonal antibodies. Pharmacol Rev 1993;45:413-453
61. Crespi CL. Xenobiotic-metabolizing human cells as tools for pharmacological and toxicological research. Adv Drug Res 1995;26:179-235
62. Parikh A, Gillam EM, Guengerich FP. Drug metabolism by escherichia coli expressing human cytochromes P450. Nat Biotechnol 1997;15: 784-788
63. Schmider J, Greenblatt DJ, Harmatz JS, et al. Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation. Br J Clin Pharmacol 1996;41: 593-604
64. Newton DJ, Wang RW, Lu AY. Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 1995;23:154-158
65. von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM, et al. Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: a model system to predict drug interactions in vivo. J Pharmacol Exp Ther 1994;268:1278-1283
66. von Moltke LL, Greenblatt DJ, Duan SX, et al. Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes. SSRI antidepressants, nefazodone, and venlafaxine. Psychopharmacology 1996; 128:398-407
67. Ko JW, Sukhova N, Thacker D, et al. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997;25:853-862
68. Hamelin BA, Trugeon J, Vallée F, et al. The disposition of fluoxetine but not sertraline is altered in poor metabolizers of debrisoquin. Clin Pharmacol Ther 1996;60:512-521
69. von Moltke LL, Greenblatt DJ, Duan SX, et al. Human cytochromes mediating N-demethylation of fluoxetine in vitro. Psychopharmacology 1997; 132:402-407
70. Stevens JC, Wrighton SA. Interaction of the enantiomers of fluoxetine and norfluoxetine with human liver cytochromes P450. J Pharmacol Exp Ther 1993;266:964-971
71. Sindrup SH, Brøsen K, Gram LF, et al. The relationship between paroxetine and the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992; 51:278-287
72. Sindrup SH, Brøsen K, Gram LF. Phamiacokinetics of the selective serotonin reuptake inhibitor paroxetine: nonlinearity and relation to the sparteine oxidation polymorphism. Clin Pharmacol Ther 1992;51:288-295
73. Bloomer JC, Woods FR, Haddock RE, et al. The role of cytochrome P4502D6 in the metabolism of paroxetine by human liver microsomes. Br J Clin Pharmacol 1992;33:521-523
74. Spigset O, Granberg K, Hägg S, et al. Relationship between fluvoxamine pharmacokinetics and CYP2D6/CYP2C19 phenotype polymorphisms. Eur J Clin Pharmacol 1997;52:129-133
75. Carrillo JA, Dahl ML, Svensson JO, et al. Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity. Clin Pharmacol Ther 1996;60:183-190
76. Spigset O, Carleborg L, Hedenmalm K, et al. Effect of cigarette smoking on fluvoxamine pharmacokinetics in humans. Clin Pharmacol Ther 1995; 58:399-403
77. Kobayashi K, Chiba K, Yagi T, et al. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes. J Pharmacol Exp Ther 1997;280:927-933
78. Rochat B, Amey M, Gillet M, et al. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes. Pharmacogenetics 1997;7:1-10
79. von Moltke LL, Greenblatt DJ, Schmider J, et al. Nefazodone in vitro: metabolic conversions, and inhibition of P450-3A isoforms [abstract]. Clin Pharmacol Ther 1996;59:176
80. Otton SV, Ball SE, Cheung SW, et al. Venlafaxine oxidation in vitro is catalysed by CYP2D6. Br J Clin Pharmacol 1996;41:149-156
81. Fogelman S, Schmider J, Greenblatt DJ, et al. Inhibition of venlafaxine metabolism in vitro by index inhibitors and by SSRI antidepressants [abstract]. Clin Pharmacol Ther 1997;61:181
82. Rudorfer MV, Potter WZ. The role of metabolites of antidepressants in the treatment of depression. CNS Drugs 1997;7:273-312
83. Schmider J, Greenblatt DJ, von Moltke LL, et al. Relationship of in vitro data on drug metabolism to in vivo pharmacokinetics and drug interactions: implications for diazepam disposition in humans. J Clin Psychopharmacol 1996;16:267-272
84. Segel IH. Enzyme Kinetics. New York, NY: John Wiley & Sons; 1975
85. Crewe HK, Lennard MS, Tucker GT, et al. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol 1992;34:262-265
86. von Moltke LL, Greenblatt DJ, Court MH, et al. Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants. J Clin Psychopharmacol 1995;15:125-131
87. Brøsen K, Skjelbo E, Rasmussen BB, et al. Fluvoxamine is a potent inhibitor of cytochrome P4501A2. Biochem Pharmacol 1993;45: 1211-1214
88. Becquemont L, Le Bot MA, Riche C, et al. Influence of fluvoxamine on tacrine metabolism in vitro: potential implication for the hepatotoxicity in vivo. Fundam Clin Pharmacol 1996;10:156-157
89. Jeppesen U, Gram LF, Vistisen K, et al. Dose-dependent inhibition of CYP1A2, CYP2C19, and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol 1996;51:73-78
90. Jeppesen U, Loft S, Poulsen HE, et al. A fluvoxamine-caffeine interaction study. Pharmacogenetics 1996;6:213-222
91. Becquemont L, Ragueneau I, Le Bot MA, et al. Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans. Clin Pharmacol Ther 1997;61:619-627
92. Hiemke C, Weigmann H, Hätter S, et al. Elevated levels of clozapine in serum after addition of fluvoxamine. J Clin Psychopharmacol 1994;14: 279-281
93. Jeppesen U, Rasmussen BB, Brøsen K. Fluvoxamine inhibits the CYP2C19-catalyzed bioactivation of chloroguanide. Clin Pharmacol Ther 1997;62:279-286
94. Schmider J, Greenblatt DJ, von Moltke LL, et al. Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin para-hydroxylation. Br J Clin Pharmacol 1997;44:495-498
95. Shader RI, Greenblatt DJ, von Moltke LL. Fluoxetine inhibition of phenytoin metabolism. J Clin Psychopharmacol 1994;14:375-376
96. Tremaine LM, Wilner KD, Preskorn SH. A study of the potential effect of sertraline on the pharmacokinetics and protein binding of tolbutamide. Clin Pharmacokinet 1997;32(suppl 1):31-36
97. Rapeport WG, Muirhead DC, Williams SA, et al. Absence of effect of sertraline on the pharmacokinetics and pharmacodynamics of phenytoin. J Clin Psychiatry 1996;57(suppl 1):24-28
98. Marino MR, Langenbacher KM, Hammett JL, et al. The effect of nefazodone on the single-dose pharmacokinetics of phenytoin in healthy male subjects. J Clin Psychopharmacol 1997;17:27-33
99. Kobayashi K, Yamamoto T, Chiba K, et al. The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4′-hydroxylase activity in human liver microsomes. Br J Clin Pharmacol 1995;40:481-485
100. Xu ZH, Xie HG, Zhou HH. In vivo inhibition of CYP2C19 but not CYP2D6 by fluvoxamine. Br J Clin Pharmacol 1996;42:518-521
101. Otton SV, Wu D, Joffe RT, et al. Inhibition by fluoxetine of cytochrome P450 2D6 activity. Clin Pharmacol Ther 1993;53:401-409
102. Shader RI, von Moltke LL, Schmider J, et al. The clinician and drug interactions: an update. J Clin Psychopharmacol 1996;16:197-201
103. Preskorn SH, Alderman J, Chung M, et al. Pharmacokinetics of desipramine coadministered with sertraline or fluoxetine. J Clin Psychopharmacol 1994;14:90-98
104. Alderman J, Preskorn SH, Greenblatt DJ, et al. Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers. J Clin Psychopharmacol 1997;17:284-291
105. Brøsen K, Hansen JG, Nielsen KK, et al. Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine. Eur J Clin Pharmacol 1993;44:349-355
106. Bergstrøm RF, Peyton AL, Lemberger L. Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992;51:239-248
107. Albers LJ, Reist C, Helmeste D, et al. Paroxetine shifts imipramine metabolism. Psychiatry Res 1996;59:189-196
108. Kurtz DL, Bergstrom RF, Goldberg MJ, et al. The effect of sertraline on the pharmacokinetics of desipramine and imipramine. Clin Pharmacol Ther 1997;62:145-156
109. Ball SE, Ahern D, Scatina J, et al. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2. Br J Clin Pharmacol 1997;43:619-626
110. Schmider J, Greenblatt DJ, von Moltke LL, et al. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O-and N-demethylation. Br J Clin Pharmacol 1996;41:339-343
111. Spina E, Gitto C, Avenoso A, et al. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study. Eur J Clin Pharmacol 1997;51:395-398
112. von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors, and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996;276:370-379
113. Greene DS, Salazar DE, Pittman K, et al. Coadministration of nefazodone and benzodiazepines, III: a pharmacokinetic interaction study with alprazolam. J Clin Psychopharmacol 1995;15:399-408
114. Barbhaiya RH, Shukla UA, Kroboth PD, et al. Coadministration of nefazodone and benzodiazepines. II: a pharmacokinetic interaction study with triazolam. J Clin Psychopharmacol 1995;15:320-326
115. Ring BJ, Binkley SN, Roskos L, et al. Effect of fluoxetine, norfluoxetine. sertraline and desmethylsertraline on human CYP3A catalyzed 1′-hydroxy midazolam formation in vitro. J Pharmacol Exp Ther 1995;275: 1131-1135
116. Bergstrom RF, Goldberg MJ, Cerimele BJ. Assessment of the potential for a pharmacokinetic interaction between fluoxetine and terfenadine. Clin Pharmacol Ther 1997;62:643-651
117. von Moltke LL, Greenblatt DJ, Duan SX, et al. Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotoninreuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. J Clin Psychopharmacol 1996;16:104-112
118. Greenblatt DJ, Preskorn SH, Cotreau MM, et al. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992;52: 479-486
119. Wright CE, Lasher-Sisson TA, Steenwyk RC, et al. A pharmacokmetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacotherapy 1992;12:103-106
120. Gardner MJ, Baris BA, Wilner KD, et al. Effect of sertraline on the pharmacokmetics and protein binding of diazepam in healthy volunteers. Clin Pharmacokinet 1997;32(suppl 1):43-49
121. Rapeport WG, Williams SA, Muirhead DC, et al. Absence of a sertraline-mediated effect on the pharmacokinetics and pharmacodynamics of carbamazepine. J Clin Psychiatry 1996;57(suppl 1):20-23
122. Perucca E, Gatti G, Cipolla G, et al. Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers. Clin Pharmacol Ther 1994;56:471-476
123. Fleishaker JC, Hulst LK. A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine. Eur J Clin Pharmacol 1994;46:35-39
124. von Moltke LL, Duan SX, Greenblatt DJ, et al. Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms. Biol Psychiatry 1997;41:377-390
125. Richelson E. Pharmacokinetic drug interactions of new antidepressants: a review of the effects on the metabolism of other drugs. Mayo Clin Proc 1997;72:835-847